No Data
No Data
Grifols Subsidiary GigaGen Awarded U.S. BARDA Contract
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
Grifols Unit Wins US Government Contract to Develop Botulinum Neurotoxin Therapy
GigaGen Awarded U.S. BARDA Contract Valued Up To $135.2M To Develop Recombinant Polyclonal Antibody Therapies For Botulinum Neurotoxins And An Additional Biothreat
Brookfield to Request More Time for Grifols Due Diligence
Market Chatter: Grifols Said to Earmark EUR360 Million for Engineering HQ in Spain